The Current Ratio as of December 2024 (TTM) for Nkarta, Inc. (NKTX) is 12.91

According to Nkarta, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 12.91. This represents a change of -13.36% compared to the average of 14.91 of the last 4 quarters.

Nkarta, Inc. (NKTX) Historical Current Ratio (quarterly & annually)

How has NKTX Current Ratio performed in the past?

The mean historical Current Ratio of Nkarta, Inc. over the last ten years is 17.37. The current 12.91 Current Ratio has changed 7.33% with respect to the historical average. Over the past ten years (40 quarters), NKTX's Current Ratio was at its highest in in the December 2020 quarter at 41.98. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Nkarta, Inc. (NKTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Nkarta, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nkarta, Inc. (NKTX) Average Current Ratio

How has NKTX Current Ratio performed in the past?

The current Current Ratio of Nkarta, Inc. (NKTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Nkarta, Inc. (NKTX) Current Ratio vs. Peers

How is NKTX’s Current Ratio compared to its peers?

Nkarta, Inc.’s Current Ratio is greater than Monte Rosa Therapeutics, Inc. (6.03), less than Lyell Immunopharma, Inc. (13.43), greater than Generation Bio Co. (6.34), greater than Sana Biotechnology, Inc. (4.47), less than Passage Bio, Inc. (0), greater than Black Diamond Therapeutics, Inc. (5.15), greater than TCR2 Therapeutics Inc. (5.55), greater than Harpoon Therapeutics, Inc. (2.77), greater than Alector, Inc. (1.89), greater than Century Therapeutics, Inc. (3.29), greater than Kezar Life Sciences, Inc. (10.39), greater than Mineralys Therapeutics, Inc. (7.65), greater than NGM Biopharmaceuticals, Inc. (8.55), greater than Revolution Medicines, Inc. (7.79), less than Atreca, Inc. (14.24), greater than null (1.58),

Build a custom stock screener for Nkarta, Inc. (NKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nkarta, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nkarta, Inc. (NKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nkarta, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.